Seasonal Influenza Activity Increasing Across Europe - H3N2 Domin...(disease/avian_influenza/guidelines/Clini...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
Date:1/19/2009
disease/avian_influenza/guidelines/ClinicalManagement07 .pdf Accessed 16 January 2009
http://www.roche.com
'/>"/>
| SOURCE Roche Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
4. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
5. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
6. DaVita Launches Flu Fighter Program in Support of National Influenza Week
7. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
8. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6
[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening[0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
Other Biology Technology:DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members 2DuPont Strengthens Commitment to Responsible Science with New Biotech Advisory Panel Members 3Biomoda Appoints Three Business Leaders to Board of Directors 2Biomoda Appoints Three Business Leaders to Board of Directors 3Spectral and Toray expand collaboration to include new geographic territories 2Spectral and Toray expand collaboration to include new geographic territories 3
Breaking Biology News(10 mins):Researchers demonstrate nanoscale X-ray imaging of bacterial cells 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Springer signs co-publishing agreement with the Royal Swedish Academy of Sciences 2Axiom Accelerated Patient Recruitment Rolls Out 58393 1Axiom Accelerated Patient Recruitment Rolls Out 58393 2Childrens Growth Charts Dont Measure Up With Parents 58390 1Childrens Growth Charts Dont Measure Up With Parents 58390 2Childrens Growth Charts Dont Measure Up With Parents 58390 3Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 1Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 2Illinois based AthletiCo Opens 53rd Physical Therapy Center in Elk Grove Village 58387 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |